Ovid Therapeutics (OVID) Share-based Compensation (2016 - 2026)

Ovid Therapeutics (OVID) has reported Share-based Compensation for 11 consecutive years, with $1.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Share-based Compensation rose 17.39% year-over-year to $1.4 million; the trailing twelve-month figure through Jun 2026 stood at $4.8 million (down 5.72% YoY), and the FY2025 full-year result was $4.8 million, down 23.41% from the prior year.
• Share-based Compensation advanced to $1.4 million in Q2 2026 per OVID's latest filing, from $1.0 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $15.8 million in Q1 2022 and bottomed at $11996.0 in Q2 2022.
• Historically, Share-based Compensation has averaged $2.3 million across 5 years, with a median of $1.4 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Share-based Compensation plunged 99.89% in 2022, then jumped 16138.75% in 2023.
• Over 5 years, Share-based Compensation stood at $11996.0 in 2022, then soared by 14813.3% to $1.8 million in 2023, then decreased by 29.57% to $1.3 million in 2024, then declined by 5.16% to $1.2 million in 2025, then gained by 19.75% to $1.4 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $1.4 million, $1.0 million, and $1.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.